SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road - 2COGAT discovers motor oil hidden inside UN's humanitarian aid to Gaza in smuggling attempt
- 3Israel faces tough choices over haredi draft exemptions, legal expert warns
- 4Moscow: Russia well-positioned to withstand oil market shocks
- 5The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- First Houthi launch toward Israel since war began triggers alerts across the Negev
- Instructions to Pick the Right Senior Protection Plan.
- Is Iran using cryptocurrencies to circumvent sanctions?
- Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- These 2 companies are teaming up to offer insurance for space debris strikes on satellites
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Discovering a true sense of harmony: Contemplation and Care Practices
